【摘要】：目的探討肺腺癌程序性死亡分子-1(programmed death 1,PD-1)、程序性死亡分子配體-1(programmed death ligand 1,PD-L1)蛋白的表達(dá)與K-RAS基因突變的相關(guān)性。方法采用免疫組化EnVision兩步法檢測(cè)PD-1、PD-L1蛋白的表達(dá),應(yīng)用實(shí)時(shí)熒光定量PCR技術(shù)檢測(cè)K-RAS基因的突變類型。結(jié)果肺腺癌組織中PD-1、PD-L1的陽性率均高于良性病變肺組織(P0.01),PD-1、PD-L1蛋白表達(dá)與患者性別、年齡、吸煙史、分化程度、淋巴結(jié)轉(zhuǎn)移及TNM分期均無相關(guān)性(P0.05)。36例肺腺癌樣本中發(fā)生K-RAS基因突變者8例(22.2%),K-RAS基因突變與患者性別、年齡、吸煙史、分化程度、淋巴結(jié)轉(zhuǎn)移及TNM分期均無關(guān)(P0.05)。相關(guān)分析顯示PD-1、PD-L1蛋白表達(dá)與K-RAS突變無關(guān)(P0.05)。結(jié)論 PD-1、PD-L1蛋白在肺腺癌中的表達(dá)明顯高于良性病變肺組織,但兩者表達(dá)程度與肺腺癌的臨床病理特征及K-RAS基因突變無關(guān)。
[Abstract]:Aim to investigate the relationship between the expression of programmed death molecule-1 (programmed death-1), programmed death molecule-1 (programmed death ligand-1), and programmed death molecule-1 (PD-L1) protein and the mutation of K-RAS gene in lung adenocarcinoma. Methods Immunohistochemical EnVision two-step method was used to detect the expression of PD-1,PD-L1 protein, and real-time fluorescence quantitative PCR was used to detect the mutation type of K-RAS gene. Results the positive rate of PD-1,PD-L1 in lung adenocarcinoma was higher than that in benign lung tissues (P0.01). The expression of PD-1,PD-L1 protein was correlated with sex, age, smoking history and differentiation degree. There was no correlation between lymph node metastasis and TNM stage (P0.05). K-RAS gene mutation occurred in 8 cases (22.2%) of 36 lung adenocarcinoma samples, and K-RAS gene mutation was associated with gender, age, smoking history and differentiation degree of the patients, and there was no correlation between K-RAS gene mutation and sex, age, smoking history and differentiation degree of lung adenocarcinoma. There was no significant difference in lymph node metastasis and TNM stage (P0.05). Correlation analysis showed that the expression of PD-1,PD-L1 protein was not associated with K-RAS mutation (P0.05). Conclusion the expression of PD-1,PD-L1 protein in lung adenocarcinoma is significantly higher than that in benign lung tissue, but it is not related to the clinicopathological features of lung adenocarcinoma and the mutation of K-RAS gene.
【作者單位】： 河北省唐山市華北理工大學(xué)附屬醫(yī)院病理科;
【基金】：2016年河北省政府資助臨床醫(yī)學(xué)優(yōu)秀人才培養(yǎng)和基礎(chǔ)課題研究(361036)
【分類號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 崔虎山,李星云,李成福,韓京軍,池永涌;三磷酸腺苷氯化鎂對(duì)肺腺癌細(xì)胞的抗癌作用[J];延邊大學(xué)醫(yī)學(xué)學(xué)報(bào);2002年03期

2 楊晉平,王澤,張?zhí)K;肺腺癌5-羥色胺受體的免疫組織化學(xué)定位[J];四川解剖學(xué)雜志;2003年02期

3 吳一龍,林嘉穎,楊學(xué)寧,喬貴賓,王坤,陳剛;肺腺癌患者酪氨酸激酶信號(hào)傳導(dǎo)通路的異常與臨床預(yù)后[J];中華醫(yī)學(xué)雜志;2004年12期

4 張利群,陳杭薇,王四海,辛慶紅,杜玉國(guó),尤蘭華;人呼吸道合胞病毒轉(zhuǎn)錄調(diào)節(jié)基因轉(zhuǎn)染肺腺癌細(xì)胞系的研究[J];山東醫(yī)藥;2005年12期

5 黎聯(lián);梅同華;周向東;張新高;車德亞;;細(xì)胞外信號(hào)調(diào)節(jié)激酶信號(hào)通路與基質(zhì)金屬蛋白酶-26在肺腺癌表達(dá)中的關(guān)系[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2009年02期

6 王亞南;顧國(guó)浩;;生物芯片在肺腺癌研究和診療中的應(yīng)用進(jìn)展[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2011年02期

7 ;我國(guó)人體肺腺癌細(xì)胞系建立[J];腫瘤;1981年06期

8 季晨陽,張義R，

本文編號(hào)：2470450